Saxenda Side Effects: Incidence Rates Across Clinical Trials

How Saxenda's Side Effect Profile Was Established

The safety database for liraglutide 3 mg rests on the SCALE (Satiety and Clinical Adiposity: Liraglutide Evidence) clinical trial program, FDA labeling, the FDA Adverse Event Reporting System (FAERS), and several post-market cohort studies. Taken together, these sources cover tens of thousands of patient-years of exposure and allow reasonably precise incidence estimates.

The SCALE Trial Program at a Glance

The SCALE program enrolled more than 5,000 adults across four phase 3 trials: SCALE Obesity and Prediabetes (N=3,731, 56 weeks), SCALE Diabetes (N=846, 56 weeks), SCALE Maintenance (N=422, 56 weeks), and SCALE Sleep Apnea (N=359, 32 weeks). Each used liraglutide 3 mg versus placebo on top of a reduced-calorie diet and increased physical activity. The pooled dataset forms the basis of the current FDA-approved prescribing information for Saxenda.

FDA Label as the Regulatory Source of Truth

The prescribing information distinguishes adverse reactions occurring in at least 5% of liraglutide-treated patients and at twice the rate of placebo from lower-frequency events. Rates quoted in the sections below come directly from that label or from the primary SCALE publications, so they reflect intention-to-treat populations with pre-specified statistical thresholds.

Post-Market Surveillance and FAERS

FAERS captures spontaneous reports after approval. Because reporting is voluntary and uncontrolled, FAERS yields signal detection rather than true incidence rates. A 2021 pharmacovigilance analysis of FAERS identified disproportionate reporting for pancreatitis, cholelithiasis, and suicidal ideation with liraglutide, prompting the FDA to add label language on mood-related events. Those FAERS signals are noted where relevant in the sections below.

Gastrointestinal Side Effects: Incidence Rates by Trial

GI adverse events are the most common reason patients reduce the dose, delay titration, or discontinue Saxenda. They are dose-dependent, mediated by GLP-1 receptor slowing of gastric emptying, and generally transient.

Nausea

In SCALE Obesity and Prediabetes, nausea occurred in 39.3% of liraglutide patients versus 14.5% on placebo. In SCALE Diabetes, nausea rates were 27.1% versus 8.5%. The lower rate in the diabetes cohort likely reflects longer prior GLP-1 exposure from background diabetes medications. Nausea peaks around week 4 to 8 (the active titration window) and drops to near-placebo rates by week 12 in most patients.

The prescribing information recommends the 5-week titration schedule specifically to reduce nausea burden: starting at 0.6 mg daily for one week, then advancing by 0.6 mg each week to reach the 3.0 mg maintenance dose. A 2020 pooled analysis published in Obesity confirmed that patients who completed the full titration had meaningfully lower discontinuation rates than those escalated faster.

Vomiting and Diarrhea

Vomiting occurred in 15.7% on liraglutide versus 3.9% on placebo in SCALE Obesity. Diarrhea was recorded in 20.9% versus 9.9%. Both effects were most pronounced during titration. SCALE Diabetes reported diarrhea in 17.5% of liraglutide patients versus 8.9% on placebo, consistent with the obesity cohort.

Constipation, less discussed but clinically significant, appeared in 19.4% on liraglutide versus 8.5% on placebo in SCALE Obesity. Constipation tends to emerge later than diarrhea and may persist longer.

Dyspepsia and Abdominal Pain

Dyspepsia affected 9.6% on liraglutide versus 2.7% on placebo. Upper abdominal pain was 5.4% versus 3.0%. These rates come from the SCALE Obesity label table and were statistically significant at P<0.001 for both comparisons.

Cardiovascular Adverse Events

Resting Heart Rate

Saxenda increases mean resting heart rate by approximately 2 to 3 beats per minute above placebo. The SCALE Obesity primary publication in NEJM reported a mean increase of +2.5 bpm versus placebo at week 56. A subset of patients (about 5% to 10%) experience increases exceeding 10 bpm. Current FDA labeling advises measuring heart rate at each clinical visit; sustained increases above 20 bpm warrant re-evaluation of therapy.

This contrasts with the cardiovascular outcome data for the lower-dose liraglutide 1.8 mg formulation (Victoza): the LEADER trial (N=9,340) showed a 13% relative reduction in major adverse cardiovascular events. The 3 mg obesity dose has no dedicated CVOT, so the cardiovascular benefit-risk calculus differs from the diabetes indication.

Blood Pressure

In SCALE Obesity, systolic blood pressure fell by a mean of 2.8 mmHg more on liraglutide than placebo, consistent with the weight-loss effect. Hypotension was not reported as a notable adverse event in any SCALE trial.

Gallbladder Disease

Gallbladder-related adverse events occurred in 2.5% of liraglutide patients versus 1.0% on placebo in SCALE Obesity, representing a statistically significant 2.5-fold increase. Cholelithiasis (gallstones) accounted for most of these events. In SCALE Diabetes, gallbladder disease was 1.5% versus 0.5%.

A 2017 meta-analysis in Alimentary Pharmacology and Therapeutics covering GLP-1 receptor agonists broadly found an odds ratio of 1.37 (95% CI 1.11 to 1.69) for cholelithiasis. Rapid weight loss itself is a confounding risk factor for gallstones, making precise attribution to the drug difficult. The Saxenda prescribing information recommends stopping therapy if cholelithiasis is confirmed by imaging.

Pancreatitis

Acute pancreatitis occurred in 0.4% of liraglutide-treated patients versus 0.1% on placebo across the pooled SCALE dataset. That absolute difference is small but statistically significant, and the FDA label carries a warning. Patients should be counseled to report persistent severe abdominal pain radiating to the back.

A 2016 systematic review in JAMA Internal Medicine evaluated pancreatitis risk across incretin-based therapies and found insufficient evidence to conclude that GLP-1 agonists cause pancreatitis at a clinically meaningful rate beyond background risk in obese patients, who already carry elevated baseline risk. The Saxenda label nonetheless instructs prescribers to discontinue the drug if pancreatitis is confirmed and to avoid it in patients with a history of pancreatitis.

Hypoglycemia

In non-diabetic patients enrolled in SCALE Obesity, documented symptomatic hypoglycemia (glucose <56 mg/dL) occurred in 1.6% on liraglutide versus 1.2% on placebo, a non-significant difference. The risk rises substantially when Saxenda is combined with a sulfonylurea or insulin. In SCALE Diabetes, where many patients used oral antidiabetics, hypoglycemia occurred in 15.1% on liraglutide versus 7.0% on placebo.

The American Diabetes Association 2024 Standards of Care recommend reducing sulfonylurea doses when initiating any GLP-1 receptor agonist.

Psychiatric and Mood-Related Events

Suicidal Ideation Signal

Following FAERS reports, the FDA issued a 2023 safety communication requiring evaluation of suicidal ideation signals across GLP-1 receptor agonists, including liraglutide. The FDA concluded in January 2024 that available data did not confirm a causal relationship. A 2024 observational study in Nature Medicine (N=240,618) found no elevated suicidal ideation risk with semaglutide, and regulatory agencies have not added a black box warning for psychiatric events for liraglutide.

Prescribers are advised to ask about mood changes and prior psychiatric history at baseline. Patients with active suicidal ideation were excluded from SCALE, so the trials do not provide direct incidence data in that subgroup.

Depression and Anxiety

In SCALE Obesity, depression was reported in 2.7% on liraglutide versus 2.5% on placebo. Anxiety occurred in 2.1% versus 1.9%. Neither difference was statistically significant. The prescribing information includes a general recommendation to monitor patients with a history of depression.

Thyroid C-Cell Tumors: The Black Box Warning

Liraglutide caused dose-dependent thyroid C-cell tumors in rodent studies. The FDA label carries a black box warning for this finding. However, the FDA review memorandum noted that rodent thyroid tissue has a much higher density of GLP-1 receptors than human thyroid tissue, making direct extrapolation uncertain.

In the SCALE trials, calcitonin levels (a marker of C-cell activity) were slightly higher in the liraglutide group but did not meet clinical thresholds. A 2021 population-based cohort study in JAMA Oncology found no statistically significant increase in medullary thyroid cancer incidence among liraglutide users compared with matched controls (HR 1.47, 95% CI 0.59 to 3.66).

Saxenda is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Injection Site Reactions

Injection site reactions affected 14.0% of liraglutide patients versus 10.6% on placebo in SCALE Obesity. Most were mild (erythema, pain, bruising) and transient. Rotating injection sites across the abdomen, thigh, and upper arm reduces local reactions.

A 2019 review of GLP-1 injection technique in Diabetes Care found that consistent rotation and avoidance of lipohypertrophic tissue lowered both local reactions and pharmacokinetic variability.

Renal and Hepatic Events

Acute kidney injury has been reported post-market, primarily as a consequence of severe volume depletion from GI fluid losses. The FDA 2016 drug safety communication on GLP-1 agonists and renal injury identified case reports with liraglutide. In the SCALE trials, eGFR remained stable or improved, likely reflecting favorable metabolic effects. Patients experiencing severe or persistent vomiting should receive proactive hydration guidance.

Hepatic adverse events were not elevated in SCALE. Alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal occurred in 0.4% on liraglutide versus 0.3% on placebo in SCALE Obesity. Fatty liver improvement has been reported in observational studies; a 2021 trial published in Hepatology Communications showed statistically significant reductions in liver fat fraction with liraglutide versus placebo.

Discontinuation Rates and Tolerability

In SCALE Obesity, 9.9% of liraglutide patients discontinued due to adverse events versus 3.8% on placebo. GI events drove the majority of discontinuations (nausea: 2.2%, vomiting: 1.4%). In SCALE Diabetes, discontinuation from AEs was 8.0% versus 3.3%.

The SCALE Maintenance trial enrolled patients who had already lost at least 5% of body weight on a low-calorie diet before randomization. Discontinuation due to AEs was 6.2% on liraglutide versus 4.8% on placebo, suggesting better tolerability in patients already adapted to caloric restriction.

Rare but Serious Adverse Events

Anaphylaxis and Angioedema

Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported post-marketing. Incidence from FAERS analysis is estimated at fewer than 1 in 10,000 patient-years, consistent with a 2022 FAERS disproportionality analysis that found reporting odds ratios below significance thresholds for severe allergic events with liraglutide. The prescribing information advises discontinuation and appropriate management if suspected.

QTc Prolongation

A dedicated thorough QT study, required by FDA for all new molecular entities, found no clinically meaningful QTc prolongation with liraglutide at therapeutic or supratherapeutic doses. The thorough QT data are summarized in the FDA clinical pharmacology review.

Lipase Elevations Without Pancreatitis

Asymptomatic lipase elevations (greater than three times the upper limit of normal) occurred in 4.0% of liraglutide patients versus 1.3% on placebo in SCALE Obesity. These elevations did not predict clinical pancreatitis in the trial dataset and the label does not recommend routine lipase monitoring in asymptomatic patients. A 2017 analysis in Diabetes Care confirmed that isolated lipase elevation without abdominal symptoms does not warrant treatment discontinuation.

Pediatric Safety Data

The FDA approved Saxenda for adolescents aged 12 and older in December 2020, based on the SCALE Teens trial (N=251) published in the New England Journal of Medicine. GI adverse event rates in adolescents were similar to those in adults: nausea in 62% of liraglutide patients versus 42% on placebo. Discontinuation due to AEs was 9.5% versus 1.6%. The higher nausea rate compared with adult trials may reflect more rigorous parental reporting or developmental differences in GI sensitivity.

Hypoglycemia occurred in 2 patients on liraglutide versus none on placebo; both cases were mild. No new safety signals emerged compared with the adult program.

Comparing Saxenda Side Effect Rates With Semaglutide 2.4 mg

Clinicians frequently ask how liraglutide 3 mg compares with semaglutide 2.4 mg (Wegovy) on tolerability. No head-to-head trial has been published as of mid-2025. The cross-trial comparison is limited by different populations, titration schedules, and trial designs.

In STEP-1 (N=1,961), nausea occurred in 44.2% on semaglutide 2.4 mg versus 15.9% on placebo. The rate is numerically higher than SCALE Obesity's 39.3%, though the placebo rate is also higher (15.9% vs. 14.5%), suggesting modest population differences. Discontinuation due to GI events was 4.3% with semaglutide in STEP-1 versus 5.2% combined GI discontinuations with liraglutide in SCALE Obesity, suggesting broadly similar GI tolerability.

The Endocrine Society 2023 Clinical Practice Guideline on Obesity states: "Both liraglutide 3 mg and semaglutide 2.4 mg are recommended for chronic weight management in adults with obesity; the choice between agents should be individualized based on efficacy, tolerability, cost, and patient preference."

Dose-Response Relationship for Adverse Events

Across GLP-1 agonist development programs, adverse event rates track dose. For liraglutide, the progression from 1.2 mg (used in early diabetes trials) to 1.8 mg (Victoza) to 3.0 mg (Saxenda) shows a clear nausea gradient. A pooled dose-finding analysis across Phase 2 liraglutide obesity trials found nausea rates of 16%, 28%, and 40% at 1.2, 2.4, and 3.0 mg respectively.

This dose-response relationship is the clinical rationale for the mandatory 5-week titration schedule. Prescribers who escalate faster to improve early weight loss typically see higher discontinuation rates, not better outcomes.